Aritinercept
Based on 1 Customer Validation
Aritinercept (AUR-200) is a recombinant fusion protein targeting TNFSF13B/BAFF/CD257. Aritinercept neutralizes BAFF and APRIL (TNFSF13), reduces B cell proliferation, suppresses peripheral B cells, lowers serum immunoglobulins. Aritinercept reduces renal damage markers, decreases IFNγ, IL-17A, and anti-dsDNA autoantibodies, and improves survival in a mouse model of SLE. ritinercept can be used for the research of systemic lupus erythematosus.
For research use only. We do not sell to patients.
- Purity: 99.9%
- CAS No.: 3057276-00-0
- Molecular Weight:61.925 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
|
IL-17A |
Aritinercept exhibits high binding affinity (Kd) to human BAFF (117 pM), human APRIL (25 pM), mouse BAFF (31 pM), and mouse APRIL (505 pM) in a cell-free surface plasmon resonance binding assay[1].
Aritinercept potently inhibits human APRIL (IC50 = 0.002 nM), mouse BAFF (IC50 = 1.5 nM), and mouse APRIL (IC50 = 2.7 nM) in a cell-free competitive ELISA, with no detectable inhibition of human BAFF[1].
Aritinercept reduces BAFF and APRIL-costimulated proliferation of human primary B cells and mouse splenocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Aritinercept (1 mg/kg; s.c.; single dose) suppresses peripheral B cells, and (5-80 mg/kg; s.c.; weekly; 4 weeks) induces sustained reductions in all serum immunoglobulins in healthy cynomolgus monkeys[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NZBxNZW F1 (randomized by body weight and proteinuria scores)[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:s.c.; weekly; 6 weeks
-
Result:Significantly improved survival at all doses tested.
Reduced proteinuria.
Decreased histological markers of renal damage.
Significantly decreased serum IFNγ and IL-17A levels at all doses.
Dose-dependently reduced serum anti-dsDNA autoantibodies.
-
Animal Model:Cynomolgus monkeys[1]
-
Dosage:1 mg/kg; 5 mg/kg; 20 mg/kg; 80 mg/kg
-
Administration:s.c.; single dose (1 mg/kg); weekly; 4 weeks (5, 20, 80 mg/kg)
-
Result:Suppressed peripheral B cells (single 1 mg/kg subcutaneous dose).
Induced sustained reductions in all serum immunoglobulins (weekly subcutaneous doses of 5, 20, or 80 mg/kg for 4 weeks).
TNFSF13B/BAFF/CD257
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
FPIA_[PROTEIN]2-FC
ELISA, FACS, Functional assay
-
Immobilized BAFF/TNFSF13B Protein, Human (CHO, HY-P7003) can bind Aritinercept. The ED50 for this effect is 0.5949 ng/mL.
Chemical Information
-
CAS No. 3057276-00-0
-
Appearance Liquid
-
Molecular Weight 61.925 kDa
-
Color Colorless to light yellow
-
SMILES
[Aritinercept]
-
Synonyms
AUR-200
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Aritinercept Related Classifications
HY-P992101 Related Classifications
Powered by Bioz